These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 24584918

  • 21. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M.
    Arthritis Res Ther; 2015 Nov 15; 17():325. PubMed ID: 26568428
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO, Duncan B, Goel N, Davies OR, Dougados M.
    Rheumatology (Oxford); 2012 Dec 15; 51(12):2204-14. PubMed ID: 22923753
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
    Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO.
    Ann Rheum Dis; 2016 Apr 15; 75(4):687-95. PubMed ID: 25795907
    [Abstract] [Full Text] [Related]

  • 32. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
    Mease PJ.
    Rheumatology (Oxford); 2011 Feb 15; 50(2):261-70. PubMed ID: 20871129
    [Abstract] [Full Text] [Related]

  • 33. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D.
    Ann Rheum Dis; 2014 Dec 15; 73(12):2094-100. PubMed ID: 23918037
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S.
    Ann Rheum Dis; 2019 Aug 15; 78(8):1033-1040. PubMed ID: 31177099
    [Abstract] [Full Text] [Related]

  • 36. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, Mease PJ.
    Ann Rheum Dis; 2014 Jan 15; 73(1):233-7. PubMed ID: 23942869
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
    Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, van Vollenhoven R, Mariette X.
    Ann Rheum Dis; 2015 Jan 15; 74(1):96-103. PubMed ID: 24092417
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K.
    Arthritis Care Res (Hoboken); 2011 Aug 15; 63(8):1142-9. PubMed ID: 21485024
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.